Akèy › Maladi Greff-versus-host › Kalifòni
Etid klinik pou Maladi Greff-versus-host nan Kalifòni
9 etid pou Maladi Greff-versus-host ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
Tèks ofisyèl etid la (Anglè)
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- UCLA Department of Medicine, Los Angeles
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07216443Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Jul 1, 2026 · NCT06996119Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- City of Hope Medical Center, Duarte
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Jun 29, 2026 · NCT06815003A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles
Ap rekriteFaz 2
Laj 2 ak plis · Tout sèks · Mizajou Jun 16, 2026 · NCT04710576A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- Stanford Cancer Center, Palo Alto
- University of California San Francisco, San Francisco
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT06615050A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
- University of California, San Francisco, San Francisco
Ap rekrite
Jiska laj 30 · Tout sèks · Mizajou Apr 13, 2026 · NCT04337515A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- City of Hope National Medical Center, Duarte
- Ronald Regan UCLA Medical Center, Los Angeles
- University of California Irvine Health, Orange
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 15, 2025 · NCT06619561Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
- Stanford Hospital, Stanford
Ap rekriteEtid obsèvasyon
36 Months · Tout sèks · Mizajou Oct 20, 2025 · NCT05866302Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- City of Hope, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2025 · NCT06462365Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.